Pain Measurement Tools Used in Women's Health Clinical Studies

Pain measurement in women’s health clinical studies requires a layered toolkit. Pain intensity, cyclical symptoms, daily impact and broader health status each need to be measured in their own way. A defensible trial design matches instruments to those tasks while weighing validation, regulatory acceptability and comparability. Specialized questionnaires let trials capture more, while physiological tools are still being developed as an alternative and have yet to become established.

Why generic pain scales fall short for women's health research

The Visual Analog Scale (VAS) and Numerical Rating Scale (NRS) remain the most widely used primary or co-primary endpoints in gynecological trials. The VAS uses a 10 cm line anchored at “no pain” and “excruciating pain,” while the NRS records a numerical intensity rating. Their strength is also their defining limit. Each captures intensity at a single moment, rather than the cyclical pattern, multiple pain sites or hormonal context of endometriosis and chronic pelvic pain. Repeated ratings can document fluctuations, but the intensity score alone does not describe their context.

Women generally experience more recurrent, more severe and longer-lasting pain than men, and their response to some drug classes differs. Those differences stem in part from differences in how hormonal, immune and neural mechanisms work. Unidimensional self-assessment is still the clinical standard, though objective pain evaluation remains hard to achieve.

How clinician-reported and early condition-specific scales tried to fill the gap

The earliest endometriosis-specific pain instruments focused on the condition but depended on clinicians to report the pain. That approach limited their validity and trial uptake. The B&B scale is one of these earlier clinician-reported tools, while the Endometriosis Pain and Bleeding Diary appeared around the same time but was never widely accepted. Condition specificity alone was not enough. Endometriosis-related pain needed a reliable, validated patient-reported outcome (PRO) measure suitable for clinical trials, and for a long time that instrument was missing.

What the Endometriosis Pain Daily Diary added and how regulators used it

The Endometriosis Pain Daily Diary (EPDD) was developed as an electronic PRO to assess endometriosis-related pain and its impact on patients’ lives. It separately captures dysmenorrhea and non-menstrual pelvic pain (NMPP), rather than treating endometriosis pain as one construct. This distinction changes what an endpoint can represent. A trial can assess menstrual and non-menstrual pain separately instead of compressing both into a single assessment. The Endometriosis Daily Pain Impact Diary became available around the same time to assess similar aspects of pain.

The EPDD validation paper describes regulatory support for further exploration in clinical trials, but does not explicitly identify it as the endpoint instrument in the elaris EM-I and EM-II studies. The main paper on those trials says they used a validated, electronic, daily 4-point pain-impact diary. The names should not be treated as interchangeable. The FDA agreement around the trials’ endpoint structure nevertheless illustrates why an acceptable validated PRO is integral to trial architecture, rather than simply an instrument with an academic validation record.

The ENDOPAIN-4D and PPIQ as the next generation of validated condition-specific instruments

The ENDOPAIN-4D advances this work through formal psychometric evaluation using COSMIN criteria. Among screened patient-reported outcome measures, it received positive ratings for six out of ten measurement properties, the highest result in that comparison. It was assessed as easy to use and effective for patient-reported endometriosis pain symptoms, with potential applications in primary care, routine follow-up and future trials as a primary outcome. Its validation also extends across languages. A Portuguese version underwent content validation followed by psychometric testing in a larger patient cohort in a 2026 publication, and a Persian version was validated in women with endometriosis.

The Pelvic Pain Impact Questionnaire (PPIQ) approaches validation through patient-derived content. Women identified affected areas of their lives, and a Delphi survey process refined their responses until consensus on the top items was reached. Its 8-item Likert-type scale covers energy, mood, sleep, gastrointestinal function, sitting tolerance, daily activities, physical activity and clothing. Higher scores indicate greater impact. Two open-ended questions address sexual activity and tampon use but do not contribute to the total score.

That development method supports the questionnaire’s content validity. The 2025 Scientific Reports validation study at the University of Pécs assessed a Hungarian adaptation, PPIQ-HU, in women with chronic pelvic pain and endometriosis, finding it reliable and valid for assessing pelvic pain in everyday life. Both instruments therefore combine patient reporting with formal scrutiny of measurement performance. Their contrast with earlier clinician-reported tools is methodological.

Where generic HRQOL measures like the SF-36 still belong in the toolkit

Generic health-related quality of life (HRQOL) measures ask about a different part of patients’ lives than condition-specific pain questionnaires do. The Medical Outcomes Study Short Form 36 (SF-36) is one of the generic HRQOL PRO measures most often used in endometriosis studies and lets researchers compare results with those of people with other diseases and with general population norms. That comparative role is indispensable to the toolkit. An endometriosis-specific instrument cannot provide the same cross-disease benchmark, even when it describes the condition more precisely.

The trade-off is sensitivity to disease-specific experience. The SF-36 may miss changes that matter to patients, while a condition-specific instrument is more likely to pick them up. Trials using both can retain a shared benchmark without making it the sole account of treatment impact. Basic intensity scales also have a reference role. The NRS serves as a convergent validity comparator in cross-cultural PPIQ validation studies, demonstrating that specialization can build on generic measurement.

The Dysmenorrhea Impact Scale and condition-specific tools for dysmenorrhea trials

Dysmenorrhea shows why this development extends beyond endometriosis. Research at Oxford’s Nuffield Department of Women’s & Reproductive Health, led by Dr. Katy Vincent, used fMRI, hormone measurement and psychological measures together to study how pain is processed. It found that women with dysmenorrhea had changes in brain processing and pain sensitivity even outside menstruation. Those findings contributed to its reclassification as a chronic pain condition in the IASP taxonomy. Measurement must consequently account for more than an isolated menstrual symptom.

Gün Kakaşçı and Demirci developed the Dysmenorrhea Impact Scale–Revised Short Form (DEÖ-R) in 2023 to capture cognitive/emotional and physiological impact. Its 13 items fall into two subdimensions and use a five-point Likert format, where higher scores show a greater impact. It broadens the assessment beyond pain intensity. Active dysmenorrhea intervention trials nevertheless continue to use the NRS and VAS as primary endpoints. Their continued use illustrates the distance between developing a dedicated instrument and incorporating it into trial practice.

How gender bias in pain assessment compounds measurement gaps in clinical settings

Instrument performance is only one part of measurement quality. A 2024 PNAS study of more than 21,000 emergency department patients found that female patients’ pain scores were less likely to be recorded by nurses. Female patients also spent approximately 30 more minutes in the emergency department and received fewer analgesics than male patients with similar complaints. These findings concern the handling of pain reports.

The broader bias evidence shows systematic underestimation of female patients’ pain and links estimation bias to stereotypes about women’s willingness to express it. Female patients are also judged more likely to benefit from psychotherapy, while male patients are seen as better candidates for pain medicine. Tarrant et al.’s 2026 Australian paper called for updated analgesia guidelines for intrauterine device insertion against this clinical backdrop. For trials, the implication concerns the data collection pathway. Direct patient reporting through electronic instruments and daily diaries reduces one opportunity for pain to be discounted or left unrecorded by an intermediary, although instrument reform alone cannot resolve clinical bias.

Why self-report itself is being challenged — and what physiological measurement offers

Pain can vary from day to day and present in different ways, making symptoms difficult for some patients to communicate accurately. Electronic daily diaries help with this difficulty, but patients still have to describe what they experience. Even a well-validated questionnaire retains this dependency. Physiological measurement aims to use signals from the body’s response to pain alongside patients’ reports or in place of them.

The autonomic nervous system provides one basis for this work, including heart rate variability and galvanic skin response. Researchers are also studying cardiovascular measures, electrodermal activity and electromyography, using classical machine learning and deep learning to turn the signals into quantified pain scores. Regulatory readiness remains the decisive constraint. None of these approaches has yet achieved regulatory designation as a primary clinical trial endpoint, and current validation work is observational. Their promise therefore does not establish their suitability for pivotal endpoint use.

Industry and academic programs trying to build objective pain measurement for women's conditions

Biofourmis and Chugai have collaborated since July 2020 on biosensor-and-AI-based pain assessment for endometriosis through the OPINE Trial. The system combines a clinical-grade wearable biosensor, an engagement app with gamification, AI for continuous pain quantification and a clinician-facing web dashboard. The system is being validated in a global observational study. The collaboration also covers virtual specialty care for endometriosis patients in the U.S. and data utilization for Chugai’s investigational product AMY109.

The Tufts team funded by the ARPA-H Sprint for Women’s Health is pursuing a composite quantitative pain score. It is screening stress hormones, inflammation markers and neurotransmitters in interstitial fluid while a monitor tracks heart rate fluctuations, galvanic skin response and breathing. Questionnaires remain part of the measurement model. Biomarker data will be merged with questionnaire responses from sites including the Defense and Veterans Center for Integrative Pain Management and Northwestern Medicine, with AI and machine learning combining the inputs.

Oxford’s PrePOSE Study addresses a related but different question. It explores whether pre-surgical MRI brain scans can predict pelvic pain reduction after endometriosis surgery, then examines questionnaires and other clinical measures as possible surrogates for the scan. Demetriou et al.’s 2026 paper in Pain established that multimodal assessment can stratify women with chronic pelvic pain. Across these programs, self-report becomes one input among several rather than the sole source of evidence. These programs are all still at the observational or early-validation stage, so their work has yet to yield an established objective endpoint.

What the proliferation of specialized instruments means for cross-trial comparability

Greater specificity creates a genuine aggregation problem. Trials using the EPDD, ENDOPAIN-4D, PPIQ, B&B or DEÖ-R do not necessarily measure the same construct, even when all describe their outcome as pain. Differences in instruments make systematic review and cross-trial comparison harder, slowing regulatory consensus. Selecting a condition-specific primary endpoint narrows the set of directly comparable studies, while proprietary wearable scores introduce a further barrier because scores across platforms are not currently comparable.

This tension does not make specialization a methodological failure. The field has built more sensitive instruments before establishing a consensus hierarchy for their use by condition, trial phase and regulatory authority. The ENDOPAIN-4D’s psychometric performance and cross-cultural validation make it a candidate for consensus adoption in endometriosis trials, but no regulatory body has formalized that position. Resolution remains an open task. Working with regulators and running cross-cultural validation programs can help build shared standards while letting trials keep condition-specific measurement.

What researchers and trial designers should understand about choosing instruments today

For trial designers, the practical lesson is to make the measurement trade-offs explicit. The VAS and NRS remain defensible intensity measures, reference anchors and secondary endpoints, but should not stand alone when a trial seeks to measure a multidimensional condition. Endometriosis instrument selection should weigh regulatory precedent for validated daily pain-impact diaries against the ENDOPAIN-4D’s strong psychometric profile, with attention to population and geography. The exact instrument identity deserves careful attention.

For chronic pelvic pain, the PPIQ is a strong candidate for measuring multidimensional impact together with an intensity scale. Generic HRQOL measures add comparability where disease-specific measures add sensitivity. Sponsors developing physiological tools should plan observational validation before using them in pivotal trials, because quantitative output alone does not establish regulatory acceptability. The defensible choice is the combination that captures the trial’s intended outcome without claiming more than its validation supports.